CRISPR Therapeutics AG
NASDAQ:CRSP

Watchlist Manager
CRISPR Therapeutics AG Logo
CRISPR Therapeutics AG
NASDAQ:CRSP
Watchlist
Price: 40.94 USD 1.14% Market Closed
Market Cap: 3.5B USD
Have any thoughts about
CRISPR Therapeutics AG?
Write Note

P/FCFE
Price to FCFE

-18.3
Current
-11.2
Median
23.4
Industry
Lower than median
Lower than industry value

Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

P/FCFE
-18.3
=
Market Cap
3.5B USD
/
FCFE
-191.2m USD
All Countries
Close
Market Cap P/FCFE
CH
CRISPR Therapeutics AG
NASDAQ:CRSP
3.5B USD -18.3
FR
Pharnext SCA
OTC:PNEXF
6T USD -3 231 766.6
US
Abbvie Inc
NYSE:ABBV
318.1B USD 12.8
US
Amgen Inc
NASDAQ:AMGN
142.2B USD 24
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD 11.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.2B USD -79.5
US
Epizyme Inc
F:EPE
94.1B EUR -424.6
AU
CSL Ltd
ASX:CSL
135.7B AUD 76.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD 23.7
US
Seagen Inc
F:SGT
39.3B EUR -58.4
NL
argenx SE
XBRU:ARGX
36.2B EUR -113.8
 
CH
CRISPR Therapeutics AG
NASDAQ:CRSP
Average P/FCFE: 29.8
Negative Multiple: -18.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -3 231 766.6
US
Abbvie Inc
NYSE:ABBV
12.8
US
Amgen Inc
NASDAQ:AMGN
24
US
Gilead Sciences Inc
NASDAQ:GILD
11.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -79.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -424.6
AU
CSL Ltd
ASX:CSL
76.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
23.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.4
NL
argenx SE
XBRU:ARGX
Negative Multiple: -113.8

P/FCFE Forward Multiples

Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/FCFE
N/A
2-Years Forward
P/FCFE
N/A
3-Years Forward
P/FCFE
N/A

See Also

Discover More